Meeting Demand: Small-Volume Mammalian Cell Culture Manufacturing

The increasing demand for biologics, evidenced by six of the top ten selling drugs in 2021 being large molecules, highlights the necessity for contract development and manufacturing organizations (CDMOs) that specialize in small-scale production of innovative pharmaceuticals and biosimilars. Startups, small to midsize biotech companies, and academic researchers require partners adept at small-volume mammalian manufacturing of biologics, such as antibodies, proteins, and cell therapies, particularly for preclinical studies and early clinical trials.

While major CDMOs focus on high-volume production for blockbuster drugs, the unique needs of smaller patient populations affected by rare diseases are often overlooked. Boutique CDMOs, like Scorpius BioManufacturing, provide tailored services with state-of-the-art facilities and expertise in mammalian cell culture. They can efficiently manage complex processes, offering cost-effective solutions for drug substance programs that require smaller volumes. Scorpius is equipped to support the entire manufacturing process, from development to clinical-scale production, ensuring that innovative therapies reach patients in need.